Detalhe da pesquisa
1.
Frailty, polypharmacy, and potentially inappropriate medications in old people: findings in a representative sample of the French population.
Eur J Clin Pharmacol
; 73(9): 1165-1172, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28601963
2.
Factors influencing report of common mental health problems among psychologically distressed adults.
Community Ment Health J
; 50(5): 597-603, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24357132
3.
Personalizing health care: feasibility and future implications.
BMC Med
; 11: 179, 2013 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23941275
4.
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
BMC Health Serv Res
; 10: 153, 2010 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-20529296
5.
Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.
Appl Health Econ Health Policy
; 8(1): 7-24, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20038190
6.
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Front Public Health
; 6: 328, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568938
7.
[Cost of obesity in France]. / Evaluation du coût associé à l'obésité en France.
Presse Med
; 36(6 Pt 1): 832-40, 2007 Jun.
Artigo
em Francês
| MEDLINE | ID: mdl-17329073
8.
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.
Front Pharmacol
; 8: 497, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28878667
9.
Entry time effects and follow-on drug competition.
Eur J Health Econ
; 17(1): 45-60, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25501258
10.
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.
Front Pharmacol
; 7: 305, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27733828
11.
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.
Front Pharmacol
; 7: 197, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27516740
12.
Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.
Pharmacoeconomics
; 33(9): 905-24, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26048353
13.
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
Expert Rev Clin Pharmacol
; 8(1): 77-94, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25487078
14.
Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy.
Joint Bone Spine
; 71(3): 214-20, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15182793
15.
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.
Front Pharmacol
; 5: 106, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24987370
16.
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.
Front Pharmacol
; 5: 109, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24959145
17.
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
Appl Health Econ Health Policy
; 11(3): 205-18, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23609765
18.
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.
Front Pharmacol
; 4: 39, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23717279
19.
Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: a time-series analysis for France 1998-2010.
Health Policy
; 102(2-3): 159-69, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21802761
20.
Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
Pharmaceuticals (Basel)
; 3(8): 2470-2494, 2010 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27713363